Everything below concerns vaccine adjuvant. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Surfactant protein D, also known as SP-D, is a lung surfactant protein part of the collagenous family of lectins called collectin. In humans, SP-D is encoded by the SFTPD gene and is part of the innate immune system. Each SP-D subunit is composed of an N-terminal domain, a collagenous region, a nucleating neck region, and a C-terminal lectin domain. Three of these subunits assemble to form a homotrimer, which further assemble into a tetrameric complex.
This success was enough for him to take over the No. 1 ranking in late October. Before the end of the season, Zverev also represented Germany in the Junior Fed Cup, leading them to a fourth-place finish. His last tournament of the year was the Grade A Orange Bowl, where he was defeated by Stefan Kozlov in the semifinals. As the top-ranked junior at the end of the season, he was named the ITF Junior World Champion, becoming the youngest boys' champion since Donald Young in 2005. Zverev played just two tournaments in 2014, both in Australia in January. He won the singles events at both tournaments, the first of which came against Australian Omar Jasika at the Traralgon Junior International. At the Australian Open, he was able to defeat Kozlov, who was seeded second, to finish his junior career with a first major title. Junior Grand Slam results – Singles: Australian Open: W (2014) French Open: F (2013) Wimbledon: 3R (2013) US Open: SF (2013)
Only some of the Ruthenian szlachta of the Chernigov region, who had their origins in the Moscow state, saved their lands from division among Cossacks and became part of the Cossack szlachta. After this, the Ruthenian szlachta refrained from plans to have a Moscow Tsar as king of the Commonwealth, its own Michał Korybut Wiśniowiecki later becoming king. The last, ultimately unsuccessful, attempt to rebuild the Polish–Cossack alliance and create a Polish–Lithuanian–Ruthenian Commonwealth was the 1658 Treaty of Hadiach. The treaty was approved by the Polish king and the Sejm, and by some of the Cossack starshyna, including hetman Ivan Vyhovsky. The treaty failed, however, because the starshyna were divided on the issue, and it had even less support among rank-and-file Cossacks.
==== Corrosion ==== In magnesium alloys, the presence of iron, nickel, copper, or cobalt strongly activates corrosion. In more than trace amounts, these metals precipitate as intermetallic compounds, and the precipitate locales function as active cathodic sites that reduce water, causing the loss of magnesium. Controlling the quantity of these metals improves corrosion resistance. Sufficient manganese overcomes the corrosive effects of iron. This requires precise control over composition, increasing costs. Adding a cathodic poison captures atomic hydrogen within the structure of a metal. This prevents the formation of free hydrogen gas, an essential factor of corrosive chemical processes. The addition of about one in three hundred parts arsenic reduces the corrosion rate of magnesium in a salt solution by a factor of nearly ten.
== History == In 2006, Rich Reiff and George Fox purchased several publications from Reed Business Information's New Product Division, formerly known as Gordon Publications, with the backing of private equity provided by Catalyst Investors. Also in 2006, the company launched the FindGuru business-to-business-focused search engine as a revised and rebranded ReedLink tool originally available from Reed Business Information. In 2011, ABM acquired Continuity Insights and Vicon Publishing. Vicon Publishing was renamed by ABM to Vicon Business Media as a subsidiary operated out of New Hampshire. In 2013 ABM acquired eMedia Vitals. In 2014, the firm was sold by Catalyst to Owners Resource Group (ORG), a private equity firm based in Austin, Texas, for undisclosed terms. This acquisition was ORG's first foray in the media business. In March 2014, co-founder Richard Reiff left the firm, leaving the CEO position vacant, though there is an indication that Jim Lonergan was brought in as CEO by the new owner. In 2018, Lonergan was replaced by Bruce Cummings and the company rebranded, changing its name to Advantage Business Marketing. On June 11, 2019, Cummings told all employees that the company was filing for bankruptcy and immediately closing. Staff had until the end of the day to vacate the premises. No severance package was given to employees, customers lost much of what they'd purchased, and many vendors were never paid.
Sources: en.wikipedia.org
== Early life == Carlisle was selected by Essendon with pick 24 in the 2009 National Draft. Like fellow draftee Jake Melksham, he is a local to the Essendon area. He played with the Calder Cannons in the TAC Cup and Craigieburn in the EDFL. He represented Vic Metro in the 2009 AFL National Under 18 Championships and was part of the 2009 Premiership team.
=== Pharmacokinetics === Oclacitinib is absorbed well when taken orally; it takes less than an hour to reach peak plasma concentration and has a bioavailability of 89%. In most dogs, pruritus begins to subside within four hours and is completely gone within 24. Oclacitinib is cleared mostly by being metabolized in the liver, though there is some kidney and bile duct clearance as well.
=== Inflammation === Because NF-κB controls many genes involved in inflammation, it is not surprising that NF-κB is found to be chronically active in many inflammatory diseases, such as inflammatory bowel disease, arthritis, sepsis, gastritis, asthma, atherosclerosis and others. Elevation of some NF-κB inhibitors, such as osteoprotegerin (OPG), are associated with elevated mortality, especially from cardiovascular diseases. Elevated NF-κB has also been associated with schizophrenia. Recently, NF-κB activation has been suggested as a possible molecular mechanism for the catabolic effects of cigarette smoke in skeletal muscle and sarcopenia. Research has shown that during inflammation the function of a cell depends on signals it activates in response to contact with adjacent cells and to combinations of hormones, especially cytokines that act on it through specific receptors. A cell's phenotype within a tissue develops through mutual stimulation of feedback signals that coordinate its function with other cells; this is especially evident during reprogramming of cell function when a tissue is exposed to inflammation, because cells alter their phenotype, and gradually express combinations of genes that prepare the tissue for regeneration after the cause of inflammation is removed. Particularly important are feedback responses that develop between tissue resident cells, and circulating cells of the immune system.
=== State of Federal Germany === After World War II, the Prussian province of Schleswig-Holstein came under British occupation. On 23 August 1946, the military government abolished the province and reconstituted it as a separate Land. On 9 September 1946, the British and Soviets offered Denmark South Schleswig, in the Septembernote. In this note, they gave Denmark carte blanche on how to deal with the German-speaking South Schleswigers, whether to integrate them into the Danish state or to forcibly expel them from South Schleswig, as was being done to Germans in Eastern Europe. Denmark's then Prime Minister, the Liberal Party's Knud Kristensen, enthusiastically accepted the offer of South Schleswig reunification with Denmark. A survey showed that 75% of the Danish population supported the incorporation, 500,000 signatures had been collected in support of it, and the Danish South Schleswig Association had sent the government a formal request for incorporation. However, the dominating Social Liberal Party feared that Denmark might again face destructive wars like the two Schleswig Wars once Germany recovered from World War II. Given that the Germans had conquered Denmark in six hours during the German invasion of Denmark, they believed Denmark would not stand a chance in such a scenario. Therefore, they pressured the Prime Minister to call for new elections, where the Liberal Party did not secure enough votes to form a government.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.